Cell Cure Neurosciences Ltd. has been awarded a grant of NIS 6.1 million for 2014 from the Office of the Chief Scientist at Israel’s Ministry of Economy. The grant will help finance the development of OpRegen, a cell-based therapeutic product for the treatment of age-related macular degeneration. The dry form of age-related macular degeneration afflicts over seven million people in the United States alone. Cell Cure’s OpRegen development plans include completion of preclinical testing and filing an IND application to commence human clinical trials in 2014. Cell Cure is a subsidiary of Bio Time Inc. (NYSE MKT: BTX) which in November bought 87,456 Cell Cure shares in exchange for 906,735 BioTime shares. BioTime owns directly and through its wholly owned subsidiary ES Cell International Pte. Ltd., 62.6% of Cell Cure.